INMD vs STAA

For growth investors, InMode Ltd.

(INMD) is the stronger pick with -6. 2% revenue growth year-over-year, versus -23. 7% for STAAR Surgical Company (STAA). InMode Ltd. (INMD) offers the better valuation at 9. 5x trailing P/E (9. 4x forward), making it the more compelling value choice. Analysts rate InMode Ltd. (INMD) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, InMode Ltd.

is actually cheaper at 9. 4x.

Over the past 5 years, InMode Ltd.

(INMD) delivered a total return of -63. 9%, compared to -79. 1% for STAAR Surgical Company (STAA). Over 10 years, the gap is even starker: STAA returned +279. 1% versus INMD's +100. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), STAAR Surgical Company (STAA) is the lower-risk stock at 0.

54β versus InMode Ltd. 's 1. 04β — meaning INMD is approximately 92% more volatile than STAA relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 11% for STAAR Surgical Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), InMode Ltd.

(INMD) is pulling ahead at -6. 2% versus -23. 7% for STAAR Surgical Company (STAA). On earnings-per-share growth, the picture is similar: InMode Ltd. grew EPS -36. 4% year-over-year, compared to -295. 1% for STAAR Surgical Company. Over a 3-year CAGR, STAA leads at -5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

InMode Ltd.

(INMD) is the more profitable company, earning 25. 3% net margin versus -33. 6% for STAAR Surgical Company — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -19. 2% for STAA. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, InMode Ltd.

(INMD) trades at 9. 4x forward P/E versus 71. 4x for STAAR Surgical Company — 62. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INMD: 17. 7% to $16. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, STAAR Surgical Company (STAA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

54), +279. 1% 10Y return). Both have compounded well over 10 years (STAA: +279. 1%, INMD: +100. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INMD is a small-cap deep-value stock; STAA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.